Avutometinib and Defactinib for Diffuse Gastric Cancer
This study is testing a combination of two oral medications, avutometinib and defactinib, for people with diffuse-type stomach cancer that has spread or cannot be removed surgically. You may be eligible if your cancer has diffuse-type cells, mixed-type cells, or specific gene changes (like CDH1 or RHOA mutations), and has continued to grow after previous chemotherapy. Avutometinib works by blocking a pathway in cancer cells called the MAP kinase pathway, specifically targeting RAF and MEK proteins. Defactinib targets a protein called FAK, which can help stomach cancer grow. The main goal is to see if this combination treatment can extend the time you live without your cancer growing or spreading. The study aims to enroll 27 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 27 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how long participants live without their cancer growing or spreading at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Avutometinib and Defactinib in Diffuse Gastric Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ryan Moy, MD, PhD · PRINCIPAL_INVESTIGATOR · Columbia University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression-free survival (PFS) Rate6 months
To determine the efficacy of combination defactinib and avutometinib in patients with metastatic diffuse gastric cancer (DGC) as measured by 6-month progression-free survival (PFS) rate. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.